Business Context and Reporting Period
This Form 8-K Current Report was filed by CG Oncology, Inc. on January 9, 2026. The filing primarily serves as a Regulation FD disclosure regarding updated clinical trial timelines and the release of topline data from two ongoing studies: the Phase 3 PIVOT-006 trial and the BOND-003 and CORE-008 trials. The Company is a clinical-stage biopharmaceutical company focused on developing cretostimogene for the treatment of non-muscle invasive bladder cancer (NMIBC).
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial data.
Material Changes and Clinical Updates
The filing details significant updates to the Company's clinical development pipeline:
- PIVOT-006 Timeline Update: The Company announced an expedited timeline for the topline data readout of the Phase 3 PIVOT-006 trial (comparing cretostimogene vs. surveillance in intermediate-risk NMIBC). Data is now expected in the first half of 2026.
- BOND-003 Cohort P Results (BCG-UR Papillary-only NMIBC):
- High-Grade Event-Free Survival (HG-EFS): Kaplan-Meier estimates at 3, 6, and 9 months were 95.7%, 84.6%, and 80.4%, respectively (as of Sept 1, 2025).
- Safety: No Grade 3 or greater treatment-related adverse events (TRAEs), no deaths, and no radical cystectomies or progression to muscle-invasive bladder cancer (MIBC).
- Enrollment: Completed with 56 patients across 35 sites in the U.S. and Japan.
- CORE-008 Cohort A Results (High-Risk, BCG-naïve NMIBC with CIS):
- Complete Response (CR) Rate: Overall CR rate was 83.7% (41/49 evaluable patients).
- Administration Comparison: The optimized two-step administration achieved an 88.0% CR rate compared to 79.2% for the original five-step administration.
- Safety: No serious adverse events, Grade 3+ adverse events, or treatment-related discontinuations. No progression to MIBC or metastatic disease.
Guidance, Outlook, and Risks
Outlook: Management highlights the potential for cretostimogene to offer best-in-disease durability and tolerability. The Company emphasizes the broad patient population in the PIVOT-006 trial, which aligns with AUA/SUO Guidelines and targets an estimated U.S. intermediate-risk population of over 50,000 patients.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Future patient data may be inconsistent with current results.
- Earlier trial results may not predict future outcomes.
- Potential for unexpected adverse side effects or inadequate efficacy.
- Delays in clinical trial commencement, enrollment, or completion.
- Competitive developments in NMIBC treatments.
The Company explicitly states it undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the specific date of the PIVOT-006 topline data readout within the first half of 2026 via future press releases.
- Review the full text of the press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) for detailed statistical analysis not summarized here.
- Check the Company's most recent Form 10-Q or 10-K for cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor for any updates on the regulatory strategy for cretostimogene following the PIVOT-006 data readout.
- Confirm the long-term durability of the Complete Response rates observed in the CORE-008 trial in future data releases.